Covidien plc Given Consensus Recommendation of “Hold” by Brokerages (NYSE:COV)
Covidien plc (NYSE:COV) has earned an average recommendation of “Hold” from the twenty brokerages that are presently covering the company, Stock Ratings Network.com reports. Eleven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $87.54.
Covidien plc (NYSE:COV) traded down 0.03% during mid-day trading on Monday, hitting $88.23. 727,638 shares of the company’s stock traded hands. Covidien plc has a 52-week low of $59.17 and a 52-week high of $92.68. The stock’s 50-day moving average is $87.95 and its 200-day moving average is $77.25. The company has a market cap of $39.858 billion and a price-to-earnings ratio of 26.62.
Covidien plc (NYSE:COV) last released its earnings data on Friday, July 25th. The company reported $1.04 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.00 by $0.04. The company had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter last year, the company posted $0.91 earnings per share. Covidien plc’s revenue was up 4.3% compared to the same quarter last year. Analysts expect that Covidien plc will post $4.02 EPS for the current fiscal year.
A number of research firms have recently commented on COV. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Covidien plc in a research note on Monday, July 28th. They now have a $101.00 price target on the stock, up previously from $81.00. Separately, analysts at Leerink Swann raised their price target on shares of Covidien plc from $93.00 to $95.00 in a research note on Monday, July 28th. They now have a “market perform” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Covidien plc from $71.00 to $95.00 in a research note on Monday, July 28th.
In other Covidien plc news, VP Coleman N. Lannum III bought 1,720 shares of Covidien plc stock on the open market in a transaction that occurred on Tuesday, August 19th. The shares were purchased at an average cost of $87.82 per share, for a total transaction of $151,050.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.
Receive News & Ratings for Covidien plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien plc and related companies with Analyst Ratings Network's FREE daily email newsletter.